ARTICLE | Company News
Acucela, Otsuka Pharmaceutical deal
October 4, 2010 7:00 AM UTC
Acucela will receive an exclusive opt-in right to co-develop and co-promote Otsuka's OPA-6566 in the U.S. for ophthalmic indications. Acucela will conduct early clinical development in the U.S. for th...